

INFORMATION DISCLOSURE STATEMENT

8 (Use several sheets if necessary)

Application Number	09/534,711
Filing Date	March 24, 2000
First Named Inventor	Philip Livingston
Art Unit	1642
Examiner Name	C. Yaen
Attorney Docket No.	1747/53437-A-PCT-US/JPW/CY

[illegible][illegible]

EXAMINER /Christopher Yaen/ (10/30/2006)
SIGNATURE

DATE CONSIDERED 10/30/2006

SIGNATURE


***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Philip O. Livingston, et al.
Serial No.: 09/534,711
Filed: March 24, 2000
Exhibit A

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Application Number	09/534,711
Filing Date	March 24, 2000
First Named Inventor	Philip Livingston
Art Unit	1642
Examiner Name	C. Yaen
Attorney Docket No.	1747/53437-A-PCT-US/JPW/CY



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	2	JENNEMANN, R., et al., "Effects of Monophosphoryllipid-A on the Immunization of Mice with Keyhole Limpet Hemocyanin- and Muramyl dipeptide-ganglioside Gfptl Conjugates," <u>J. Biochem.</u> , 119(2):378-384, (1996);	
CY	3	KIM, S. K., et al., "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates", <u>Vaccine</u> , 19:530-537 (2001);	
CY	4	LIVINGSTON, P. O., "Approaches to Augmenting the Immunogenicity Of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines," <u>Immunological Reviews</u> , 145:147-166 (1995); and	
CY	5	RAGUPATHI, G., et al., "Induction Of Antibodies Against GD3 Ganglioside In Melanoma Patients By Vaccination With GD3-Lactone-KLH Conjugate Plus Immunological Adjuvant QS-21", <u>Int. J. Cancer</u> , 85:659-666 (2000).	

EXAMINER
SIGNATURE / Christopher Yaen/ (10/30/2006)

DATE CONSIDERED 10/30/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.